Aurisco Pharmaceutical Co Ltd (605116) - Total Liabilities

Latest as of June 2025: CN¥1.47 Billion CNY ≈ $215.58 Million USD

Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) has total liabilities worth CN¥1.47 Billion CNY (≈ $215.58 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aurisco Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Aurisco Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Aurisco Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Aurisco Pharmaceutical Co Ltd.

Aurisco Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Aurisco Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Wuxi ETEK Microelectronics Co Ltd SHG:688601	China	CN¥133.17 Million
Metropolitan Kentjana Tbk JK:MKPI	Indonesia	Rp2.24 Trillion
Ladder Capital Corp Class A NYSE:LADR	USA	$4.18 Billion
Pearl Global Industries Limited NSE:PGIL	India	Rs-14.38 Billion
Ningbo Sunrise Elc Technology Co Ltd Class A SHE:002937	China	CN¥938.74 Million
Shinva Medical Instrument Co Ltd SHG:600587	China	CN¥6.91 Billion
Chutian Dragon Co Ltd SHE:003040	China	CN¥536.63 Million
WindSun Science & Technology Co. Ltd. A SHG:688663	China	CN¥2.02 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Aurisco Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Aurisco Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.51	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.38	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aurisco Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aurisco Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual total liabilities of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.55 Billion ≈ $226.21 Million	+154.67%
2023-12-31	CN¥607.03 Million ≈ $88.83 Million	+74.09%
2022-12-31	CN¥348.68 Million ≈ $51.02 Million	+63.37%
2021-12-31	CN¥213.44 Million ≈ $31.23 Million	+44.23%
2020-12-31	CN¥147.98 Million ≈ $21.65 Million	+20.34%
2019-12-31	CN¥122.96 Million ≈ $17.99 Million	-7.65%
2018-12-31	CN¥133.16 Million ≈ $19.48 Million	+0.54%
2017-12-31	CN¥132.44 Million ≈ $19.38 Million	-31.03%
2016-12-31	CN¥192.01 Million ≈ $28.10 Million	--

About Aurisco Pharmaceutical Co Ltd

SHG:605116 China Biotechnology

Market Cap

$1.19 Billion

CN¥8.16 Billion CNY

Market Cap Rank

#8215 Global

#1923 in China

Share Price

CN¥20.08

Change (1 day)

-0.50%

52-Week Range

CN¥18.37 - CN¥34.43

All Time High

CN¥34.43